Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial

British Journal of Haematology

Volumn 147, Issue 5, 2009, Pages 677-680

  Gertz, Morie A ^a   Abonour, Rafat ^b   Heffner, Leonard T ^c   Greipp, Philip R ^a   Uno, Hajime ^d   Rajkumar, S V ^a  

^a MAYO CLINIC   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY CLINIC   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Lymphoplasmacytic lymphoma; Monoclonal IgM protein; Rituximab; Waldenstr m macroglobulinaemia

Indexed keywords

IMMUNOGLOBULIN M; RITUXIMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 70449356982     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07892.x     Document Type: Article

References (12)

1. Dhodapkar, M.V., Jacobson, J.L., Gertz, M.A., Crowley, J.J. Barlogie, B. (2003) Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SWOG S9003). Seminars in Oncology, 30, 220 225.
2. Dhodapkar, M.V., Hoering, A., Gertz, M.A., Rivkin, S., Szymonifka, J., Crowley, J. Barlogie, B. (2009) Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 113, 793 796.
3. Dimopoulos, M.A., Alexanian, R., Gika, D., Anagnostopoulos, A., Zervas, C., Zomas, A., Kyrtsonis, M.C., Anagnostopoulos, N., Pangalis, G.A. Weber, D.M. (2004) Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leukemia and Lymphoma, 45, 2057 2061.
4. Fonseca, R. Hayman, S. (2007) Waldenström macroglobulinaemia. British Journal of Haematology, 138, 700 720.
5. Gertz, M.A., Anagnostopoulos, A., Anderson, K., Branagan, A.R., Coleman, M., Frankel, S.R., Giralt, S., Levine, T., Munshi, N., Pestronk, A., Rajkumar, V. Treon, S.P. (2003) Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 121 126.
6. Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukemia and Lymphoma, 45, 2047 2055. (Pubitemid 39232853)
7. Kimby, E., Treon, S.P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M. Blade, J. (2006) Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clinical Lymphoma and Myeloma, 6, 380 383.
8. Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A.I., Clark, B., Lucas, M.S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K.C. Byrd, J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy, 24, 272 279.
9. Treon, S.P., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Branagan, A.R., Anderson, K.C. Frankel, S.R. Waldenström's Macroglobulinemia Clinical Trials Group 2005) Extended rituximab therapy in Waldenström's macroglobulinemia. Annals of Oncology, 16, 132 138.
10. Treon, S.P., Gertz, M.A., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A.R., Garcia-Sanz, R., Johnson, S., Kimby, E., Leblond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R. Stone, M.J. (2006) Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood, 107, 3442 3446.
11. Weber, D., Treon, S.P., Emmanouilides, C., Branagan, A.R., Byrd, J.C., Blade, J. Kimby, E. (2003) Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 127 131.
12. Witzens-Harig, M., Reiz, M., Heiss, C., Benner, A., Hensel, M., Neben, K., Dreger, P., Kraemer, A. Ho, A.D. (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Annals of Hematology, 88, 51 57.